Stereotactic Radiosurgery as Treatment for Brain Metastases: An Update

Isabela Peña-Pino1 Clark C. Chen2

1 Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, United States
2 Department of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, United States

AJNS 2023;18:246–257.

Address for correspondence Clark C. Chen, MD, PhD, Lyle A. French Professor and Chair, Department of Neurosurgery, University of Minnesota, Medical School, D429 Mayo Memorial Building, 420 Delaware St. S. E., MMC96, Minneapolis, MN 55455, United States (e-mail: ccchen@umn.edu).

Abstract

Keywords ► brain metastases ► stereotactic radiosurgery ► cumulative intracranial tumor volume ► stereotactic laser ablation

Stereotactic radiosurgery (SRS) is a mainstay treatment option for brain metastasis (BM). While guidelines for SRS use have been outlined by professional societies, consideration of these guidelines should be weighed in the context of emerging literature, novel technology platforms, and contemporary treatment paradigms. Here, we review recent advances in prognostic scale development for SRS-treated BM patients and survival outcomes as a function of the number of BM and cumulative intracranial tumor volume. Focus is placed on the role of stereotactic laser thermal ablation in the management of BM that recur after SRS and the management of radiation necrosis. Neoadjuvant SRS prior to surgical resection as a means of minimizing leptomeningeal spread is also discussed.

Introduction

Brain metastasis (BM) affects 20 to 40% of cancer patients, translating to approximately 170,000 cases in the U.S. each year.1 While brain metastases can arise from virtually any cancer, they are most commonly found in patients afflicted with lung cancer (19.9%), melanoma (6.9%), renal cell carcinoma (RCC) (6.5%), breast cancer (5.1%), and colorectal cancer (1.8%).2 Patients with HER2 breast cancer, triple negative breast cancer, melanoma, small cell lung cancer, and non-squamous/non-small cell lung cancer (NSCLC) have the highest risk of developing brain metastases.3 The majority of BM patients present with oligometastatic disease, typically defined as 1 to 3 intracranial lesions.4 Tumors such as melanoma and RCC have higher propensities for intracranial invasion relatively early during clinical course while breast and colorectal cancer invade the central nervous system after systemic metastases have been established.5

In this review, we will provide an overview of stereotactic radiosurgery (SRS) as a treatment for BM. Emphasis will be placed on efficacy, prognostic variables, patient selection, and complications.

Diagnosis and Prognosis

Any cognitive decline or acute neurological symptom in a patient diagnosed with cancer merits prompt imaging workup. Approximately 90% of patients with brain metastases suffer neurocognitive decline prior to diagnosis.6 For workup, the gold standard diagnostic tool is a thin axial magnetic resonance imaging (MRI) performed after administration of contrast material. On T1 imaging, brain metastases are typically solid, contrast-enhancing masses located at the gray-white junction. Magnetic resonance spectroscopy tends to demonstrate high choline/N-acetylaspartate and choline/ creatinine ratios in the contrast-enhancing regions.7 BM
from melanomas, choriocarcinomas, germ cell tumors, thyroid cancer, and RCC are more likely to be hemorrhagic.\textsuperscript{8} The prognosis of patients with brain metastases is poor, with a median survival of 4 months after whole brain radiation therapy (WBRT) and 1-year survival of 12%.\textsuperscript{9,10} However, survivors beyond historical expectations are beginning to emerge as improved systemic therapy becomes available through targeted agents and immunotherapies.\textsuperscript{11,12} Clinical variables that prognosticate survival can be divided into three categories: patient demographics and clinical condition (age, Karnofsky Performance Score [KPS] greater, systemic disease control), BM characteristics (cumulative intracranial tumor volume [CITV], number of BM), and the presence of targetable mutations (e.g., BRAF mutation). The relative importance of these prognostic factors varies as a function of the specific cancer type\textsuperscript{13} and cancer-specific prognostic scales have been developed for BM patients. These scales aid in clinical decision making in terms of palliative versus curative intent.\textsuperscript{14}

**Treatment Options**

Because most systemic therapies poorly penetrate the blood–brain barrier, their application as therapies for BM require participation in pertinent clinical trials or the discretion of the treating oncologist. It is important to note that some BMs do respond to systemic therapy, particularly for smaller sized lesions.\textsuperscript{15}

Surgical resection is considered for patients with oligometastatic disease with symptomatic mass effect. Resection or biopsy is also warranted in cases of diagnostic uncertainty.\textsuperscript{16} Additionally, randomized controlled trials demonstrate improved survival in patients with solitary BM who underwent surgical resection followed by radiation therapy relative to those treated with radiation therapy alone.\textsuperscript{17,18} Importantly, surgical resection should be followed with radiation of the resection cavity, since approximately 50% of resected tumors recur locally without such treatment.\textsuperscript{19}

Radiation therapy remains a mainstay option for the treatment of BM and can be applied to the entire brain, as WBRT or only to the BM (SRS). In WBRT, radiation is delivered in small fractions on a daily basis. It is highly effective in achieving local control of tumor growth.\textsuperscript{20} Most studies report local control rate of over 80%.\textsuperscript{21–24} Because the entire cerebrum is radiated, WBRT “sterilizes” regions of the brain that are not affected by the macroscopic tumor. Since these regions may harbor micrometastatic foci that were invisible to the original MRI, WBRT minimizes the likelihood of new BM distant to the original tumor site (termed distant metastasis). This control of distant metastasis comes at the cost of injury to the cerebrum and neurocognitive decline following treatment. In two independent clinical trials, oligometastatic BM patients with WBRT exhibited worsened verbal memory capacity relative to those treated with SRS.\textsuperscript{2,25} In general, current clinical practice employs WBRT for: prophylactic cranial irradiation for small cell lung cancers, treatment of miliary BM, or treatment with palliative intent.\textsuperscript{8,26} SRS involves technology platforms that converge multiple, nonparallel beams to deliver a single, high radiation dose to a targeted region.\textsuperscript{27,28} The radiation delivered through SRS is highly conformal to the lesion, with a rapid dose fall-off at the edge of the treatment volume.\textsuperscript{3} With the exception of highly radiation resistant tumors, such as melanomas and sarcomas, SRS is highly efficacious as a means of controlling BM growth.\textsuperscript{29,30} Since SRS spares cerebrum unaffected with BM, there is a decreased likelihood of posttreatment neurocognitive decline relative to WBRT.\textsuperscript{4,25,31} Moreover, because higher doses can typically be delivered through SRS, local control is improved relative to WBRT.\textsuperscript{29,30,32} However, repeat radiosurgery as treatment for distant recurrence is often required.\textsuperscript{30} As such, continued imaging surveillance is required for patients who undergo SRS.

While WBRT and SRS differ in the control of local and distant BM, most studies indicate comparable survival after either treatment.\textsuperscript{4,29} These observations are largely consistent with studies demonstrating uncontrolled systemic disease as the main cause of cancer death.\textsuperscript{33,34} In this context, while there is an extended literature describing the effects of combining SRS with WBRT,\textsuperscript{4,20,29,35} this practice is not routinely applied in the current clinical practice.

**Platforms for SRS**

The concept of SRS was first introduced by Leksell in 1951 with the use of several proton beams and later on the gamma beams.\textsuperscript{36} Since this initial landmark development, multiple technology platforms have been developed to facilitate SRS. These technology platforms bear distinct commercial names, including Gammaknife,\textsuperscript{37} Cyberknife,\textsuperscript{38} Edge,\textsuperscript{39} Hyperarc,\textsuperscript{40} ZAP,\textsuperscript{41} and proton beam radiosurgery.\textsuperscript{42} While the mechanisms of radiation delivery differ between these platforms, the available literature suggests comparable clinical efficacy.\textsuperscript{43}

**Considerations for SRS Treatment**

**Dose, Fraction, and Anatomic Considerations**

Based on a landmark study by the Radiation Therapy Oncology Group (RTOG), the maximum tolerated SRS doses for tumors less than 20, 21 to 30, and 31 to 40 mm were 24, 18, and 15 Gy, respectively.\textsuperscript{37} More current clinical applications utilize doses below the thresholds defined by this study. Dose deescalation when treating lesions in proximity of radiation sensitive structures, such as the optic nerve and the brainstem are routinely performed.\textsuperscript{45}

Historically, SRS requires headframe placement and is typically delivered in a single treatment. With improvement in methods for immobilization as well as time required for delivery, frameless SRS is now possible. For larger lesions, patients can undergo hypofractionated SRS, defined as up to five treatments of conformation radiation delivery.\textsuperscript{46} An alternative approach for SRS of larger lesions involves staged SRS, where SRSs are separated by short time intervals or sequentially delivered to different regions of the lesion.\textsuperscript{47} Efficacy of these treatment variations for larger lesions are
largely comparable to single fraction radiosurgery for smaller lesions. Dose equivalent radiation delivered through fractionation has been shown to decrease posttreatment morbidity (Lau et al).48

**Prognostic Scales**

Survival prognostication serves as a key foundation for tailoring therapy to BM patients. Several prognostic scales have been developed for SRS-treated BM patients (Table 1). The earlier prognostic scales, including the recursive partitioning analysis (RPA), modified RPA, Score Index for Radiosurgery, Basic Score for Brain Metastasis, and Graded Prognosis Analysis (GPA),48–53 treated BM as a single entity, irrespective of the original cancer diagnosis. These studies highlight the prognostic importance of patient demographics and clinical condition as well as BM characteristics. In recent studies, there is increased appreciation that BM derived from cancers of distinct histology exhibit differing clinical courses and that prognostic scales need to be tailored to distinct tumor types. The disease-specific GPA was developed in this context (Table 2). With the emergence of therapies targeting oncogenic mutations, such as BRAF and EGFR, modern prognostic scales now incorporate tumor mutation status as a prognostic factor.

Published studies suggest other variables that warrant consideration as prognostic factors. In one study of lung cancer BM, tumors that were more spherical in morphology were associated with better local control after SRS.57 In another study, a pretreatment biological measure, the neutrophil-to-lymphocyte ratio, appeared to predict both local failure and SRS and poor survival.58 Finally, radiomic features of NSCLC BM have also been associated with prognosis. A study analyzing 576 NSCLC brain metastases in 161 patients treated with SRS identified select radiomic features of BM on MRI that were associated with clinical survival.59 Future prognostic scales should consider incorporation of these variables.

**Number of Brain Metastases**

The Congress of Neurological Surgeons (CNS) 2019 Guidelines for the use of SRS for the treatment of metastases in adults provide level 3 recommendations for the use of SRS as treatment of patients presenting with 2 to 4 BM.60 This recommendation should be considered in the context of the study by Yamamoto et al, who conducted a prospective study of 1,194 SRS-treated BM patients. While the overall survival for patients with one BM (13.9 months) was improved relative to those with 2 to 10 BM (10.8 months), there were no significant differences in overall survival between those with 2 to 4 BM and those with 5 to 10 BM.61 In the largest retrospective study to date, Ali et al analyzed 5,750 patients treated with SRS for BM and recapitulated the findings reported by Yamamoto et al.62 Other studies have reported similar findings.63,64,66 Moreover, in patients with more than 4 lesions, there is level 3 evidence for the use of SRS to improve overall survival when the cumulative volume is less than 7 mL.60 These studies support consideration for SRS in the treatment of more than 4 BM in select circumstances. The findings that lesion size,63,64 patient KPS,30 and tumor histology13,63 influence local control following SRS treatment of multiple BM bear relevance to this decision.

**Cumulative Intracranial Tumor Volume**

CITV is defined as the sum of the volume of all BM detected at the time of diagnosis. It is an important prognostic factor for patients afflicted with SRS. In general, maximal radiation dose that can be safely delivered during SRS is inversely proportional to the volume of the BM. As such, dose deescalation is often required in the treatment of BM with larger CITV.64 Moreover, BM with larger CITV is more likely to be associated with mass effect, which portends to poor prognostication. Finally, larger CITV may reflect an aggressive biology, which necessarily impacts survival prognostication.

The CNS 2019 Guidelines for the use of SRS for the treatment metastases in adults provide level 3 recommendations for the use of SRS in the treatment of BM with cumulative volume of less than 7 mL. However, it is important to keep in mind that the prognostic threshold for CITV differs depending on the cancer histology. For instance, the prognostic CITV threshold for colorectal BM is 10 mL while the prognostic CITV threshold for lung cancer, melanoma, and RCC. In contrast, CITV does not influence survival in breast cancer who undergo SRS treatment for BM.67 In this context, the 7-mL guideline is more of an “average” of the prognostic threshold for the various cancer types. It is important to bear this observation in mind when considering the CNS guidelines.

Additionally, it is essential to recognize that because of the heterogeneity in the volume of BMs, the number of BM does not always correlate with the CITV. In multiple studies, CITV and number of BM constitute independent prognostic factors.45,65,68,69 Thoughtful consideration of these variables in the context of cancer histology, patient condition, and molecular profile of the BM is warranted.

**Complications**

**Recurrent Brain Metastasis**

Depending on tumor histology and CITV, up to 30% of SRS-treated BM recur. Although repeated SRS treatments of these lesions are feasible, they are associated with increased risk for radiation necrosis (RN) and treatment failure. As such, stereotactic laser ablation (SLA) represents an alternative therapeutic option. SLA involves the insertion of a fiber-optic probe into the lesion, followed by laser activation to trigger thermocoagulation (Fig 1). As a stand-alone treatment for BM that recur after SRS, local control is largely influenced by the percent of tumor ablation.71 Tumor recurrence is more likely when the ablation is incomplete. In completed ablated BM, reported local control is consistently above 80%.74 However, incomplete ablation can be safely combined with repeat, hypofractionated SRS to improve local control. Importantly, SLA has been shown to improve quality of life for patients suffering from BM that recurred after SRS.73
Table 1  Summary of nontumor-specific prognostic scales

<table>
<thead>
<tr>
<th>Year of publication</th>
<th>Number of patients</th>
<th>Prognostic variables</th>
<th>Resulting parameter</th>
<th>Median overall survival (mo)</th>
</tr>
</thead>
</table>
| **RPA**<sup>48</sup> | 1997               | 1,200                | Age (y)  
KPS  
Primary tumor control  
Tumor number  
Non-brain metastases  
Largest tumor volume (cm³) | Class I: Age < 65,  
KPS > 70, and primary tumor control  
Class II: All others  
Class III: KPS < 70 | Class I: 7.1  
Class II: 4.2  
Class III: 2.3 |
| **Modified-RPA for class II**<sup>29</sup> | 2012               | 3,753                | Age (All ≥ 65)  
KPS (All KPS < 70)  
Primary tumor control  
Tumor number  
Non-brain metastases  
Largest tumor volume (cm³) | Class IIa: score of 0–1  
Class IIb: score of 2  
Class IIc: score of 3–4 | Class IIa: 19.7–15.6  
Class IIb: 8.4  
Class IIc: 5.2–3.5 |
| **Modified-RPA for class III**<sup>50</sup> | 2002               | 916                  | Age (All ≥ 65)  
KPS (All KPS < 70)  
Primary tumor control  
Tumor number  
Non-brain metastases  
Largest tumor volume (cm³) | Class IIIa: Age < 65,  
primary tumor control, single lesion  
Class IIIb: All others  
Class IIIc: Age ≥ 65,  
uncontrolled primary tumor, multiple lesions | Class IIIa: 3.2  
Class IIIb: 1.9  
Class IIIc: 1.2 |
| **SIR**<sup>51</sup> | 2000               | 65                   | 0: ≥ 60  
1: 51–59  
2: ≤ 50  
0: ≤ 50  
1: 50–70  
2: ≥ 70  
0: PD  
1: PR–SD  
2: CR–NED  
0: ≥ 3  
1: 2  
3: 1  
0: > 13  
1: 5–13  
2: < 5 | Score range of 0–10 | Score 1–3: 2.9  
Score 4–7: 7.0  
Score 8–10: 11.38 |
| **BS-BM**<sup>52</sup> | 2004               | 110                  | Age (All ≥ 65)  
KPS (All KPS < 70)  
Primary tumor control  
Tumor number  
Non-brain metastases  
Largest tumor volume (cm³) | Score range of 0–3 | Score 0: 1.9  
Score 1: 3.3  
Score 2: 13.1  
Score 3: Undefined |
| **GPA**<sup>53</sup> | 2008               | 1,960                | 0: ≥ 60  
0.5: 50–59  
1: < 50  
0: ≤ 70  
0.5: 70–80  
1: 90–100  
0: ≥ 3  
0.5: 2–3  
1: 1  
0: Present None  
1: None | Score range of 0–4 | Score 0–1: 2.6  
Score 1.5–2.5: 3.8  
Score 3: 6.9  
Score 3.5–4: 11.0 |

Abbreviations: BS-BM, Basic Score for Brain Metastasis; CR, complete clinical remission; GPA, Graded Prognosis Analysis; KPS, Karnofsky Performance Score; NA, not applicable; NED, no evidence of disease; PD, progressive disease; PR, partial remission; RPA, recursive partitioning analysis, SD, stable disease; SIR, Score Index for Radiosurgery.
Table 2: Summary of tumor-specific prognostic scales

<table>
<thead>
<tr>
<th>Year of publication</th>
<th>Number of patients</th>
<th>Prognostic variables</th>
<th>Tumor number</th>
<th>Non-brain metastases</th>
<th>Gene status</th>
<th>Resulting parameter</th>
<th>Median overall survival (mo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ds-GPA (lung - NSCLC and SCLC)</td>
<td>2008</td>
<td>4,529</td>
<td>Age (y)</td>
<td>KPS</td>
<td>0: &gt; 60 0.5: 50–59 1: &lt; 50</td>
<td>0: &lt; 70 0.5: 70–80 1: 90–100</td>
<td>0: &gt; 3 0.5: 2–3 1: 1</td>
</tr>
<tr>
<td>ds-GPA (lung)</td>
<td>2017</td>
<td>2,186</td>
<td>0: ≥ 70 0.5: &lt; 70</td>
<td>0: &lt; 70 0.5: 70–80 1: 90–100</td>
<td>0: &gt; 4 0.5: 1–4</td>
<td>0: Present 1: Absent</td>
<td>0: EGFR neg/unk and ALK neg/unk 1: EGFR pos or ALK pos</td>
</tr>
<tr>
<td>ds-GPA (melanoma and RCC)</td>
<td>2008</td>
<td>4,529</td>
<td>NA</td>
<td>0: &lt; 70 1: 70–80 2: 90–100</td>
<td>0: &gt; 5 1: 2–3 2: 1</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>ds-GPA (melanoma)</td>
<td>2017</td>
<td>823</td>
<td>0: ≥ 70 0.5: &lt; 70</td>
<td>0: &lt; 70 0.5: 70–80 1: 90–100</td>
<td>0: &gt; 4 0.5: 2–4 1: 1</td>
<td>0: Present 1: Absent</td>
<td>0: BRAF neg/unk 1: BRAF pos</td>
</tr>
<tr>
<td>ds-GPA (GI and breast)</td>
<td>2008</td>
<td>4,529</td>
<td>NA</td>
<td>0: &lt; 70 1: 70 2: 80 3: 90 4: 100</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: AdenoCa, adenocarcinoma; ALK, anaplastic lymphoma kinase; ds-GPA, diagnosis-specific Graded Prognostic Assessment; EGFR, endothelial growth factor; GI, gastrointestinal; KPS, Karnofsky Performance Score; NA, not applicable; neg/unk, negative/unknown; NSCLC, nonsmall cell lung cancer; pos, positive; RCC, renal cell carcinoma; SCLC, small cell lung cancer.

*Same scale as original GPA.
Distant Recurrence

Although SRS provides good local tumor control, lesions distant to the original treated site can develop. In patients who suffer distant BM after initial SRS, the duration between the two treatments is approximately 6 months.\textsuperscript{45,70,74} Additionally, approximately 20\% of patients require more than one additional SRS as treatment of distant BM. The actuarial freedom from progression of the retreated tumors at 52 weeks is 92.4\%\textsuperscript{74} and local control rate at 6 months after salvage SRS is 90.7\%.\textsuperscript{70} Importantly, patients who received repeated SRS were more likely to be younger, have control of systemic disease, have metastases with smaller cumulative total volume, and suffer from melanoma, indicating a bias in patient selection for consideration of repeat SRS.\textsuperscript{45} Repeat SRS of distant lesions improves quality of life for treated patients in terms of improving neurologic function as well as discontinuation of corticosteroids.\textsuperscript{75}

Multiple repeat SRS treatments, however, are associated with a risk for neurologic morbidity, including radionecrosis, nonspecific fluid-attenuated inversion recovery (FLAIR) signal abnormalities, cyst formation seizures, and hemorrhage.\textsuperscript{63,76–79}

Fig. 1 Thermometry of stereotactic laser ablation. Panels (A) (preablation magnetic resonance imaging [MRI]) and (C) (thermometry) represent coronal images; (B) (preablation MRI) and (D) (thermometry) demonstrate sagittal images. Panels (E) (preablation MRI) and (G) (thermometry) represent coronal images of the same patient in a second ablation; panels (F) (preablation MRI) and (H) (thermometry) demonstrate sagittal images. Temperature gradient demonstrated as heat maps. Orange pixels indicate regions of irreversible thermal damage. Arrows indicate insertion site. Asterisks indicate probe tip location.
Table 3 Neoadjuvant versus adjuvant SRS

<table>
<thead>
<tr>
<th>Year of publication</th>
<th>Type of study and cohort size</th>
<th>Groups</th>
<th>BM characteristics</th>
<th>Outcomes</th>
<th>Local recurrence</th>
<th>Overall survival</th>
<th>Radiation necrosis incidence</th>
<th>Leptomeningeal disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prabhu et al 2017</td>
<td>Retrospective, 213 (223 BM)</td>
<td>1. SRS alone (n = 157) 2. Gross total resection + SRS (n = 63 neoadjuvant, n = 94 adjuvant)</td>
<td>Large BM (≥ 4 cm³)</td>
<td>1-year recurrence rate 1. 36.7% 2. 20.5%</td>
<td>2 year OS rate 1. 19.8% 2. 38.9%</td>
<td>1 year rate 1. 1.9% 2. 5.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mahajan et al 2017</td>
<td>Randomized controlled, 132</td>
<td>1. Resection alone (n = 68) 2. Gross total resection + adjuvant SRS (n = 64)</td>
<td>Resection of 1–3 BM, resection cavity diameter of ≤ 4 cm</td>
<td>1-year recurrence-free rate 1. 43% 2. 72%</td>
<td>Median OS time 1. 18 months 2. 17 months</td>
<td>NA</td>
<td>1 year rate 1. 16% 2. 28%</td>
<td></td>
</tr>
<tr>
<td>Johnson et al 2016</td>
<td>Retrospective, 330</td>
<td>1. SRS alone (n = 218) 2. Gross total resection + adjuvant SRS (n = 112)</td>
<td>1–4 BM</td>
<td>NA</td>
<td>Median OS time 1. 10.6 months 2. 12.9 months</td>
<td>NA</td>
<td>1 year rate 1. 5.2% 2. 16.9%</td>
<td></td>
</tr>
<tr>
<td>Prabhu et al 2018</td>
<td>Retrospective, 117 (125 BM)</td>
<td>Neoadjuvant SRS + gross total resection</td>
<td>70% of patients with 1 BM</td>
<td>1-year recurrence rate: 19.9% 2-year recurrence rate: 25.1%</td>
<td>Median OS time: 17.2 months OS 2-year rate: 36.7%</td>
<td>1 year rate 1. 5.1% 2 year rate 8.1%</td>
<td>1 and 2 year rate: 4.3%</td>
<td></td>
</tr>
<tr>
<td>Patel et al 2016</td>
<td>Retrospective, 180</td>
<td>1. Neoadjuvant SRS + resection (n = 66) 2. Resection + adjuvant SRS (n = 114)</td>
<td>90% of patients had 1–3 BM</td>
<td>1-year recurrence rate 1. 15.9% 2. 12.6%</td>
<td>Median OS time 1. 17.1 months 2. 13.5 months</td>
<td>2 year rate 1. 4.9% 2. 16.4%</td>
<td>2 year rate 1. 3.2% 2. 16.6%</td>
<td></td>
</tr>
<tr>
<td>Patel et al 2018</td>
<td>Retrospective, 12</td>
<td>Neoadjuvant SRS + surgical resection</td>
<td>Median tumor diameter: 3.66 cm</td>
<td>6-month tumor control rate: 81.8% 1-year tumor control rate: 49.1%</td>
<td>OS rate at 1 year: 74.1%</td>
<td>No evidence of RN</td>
<td>1 year rate 16% (n = 2)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BM, brain metastasis; NA, not applicable; OS, overall survival; RN, radiation necrosis; SRS, stereotactic radiosurgery.

*Non-significant differences between groups.
<table>
<thead>
<tr>
<th>Study</th>
<th>Year of publication</th>
<th>Cohort</th>
<th>Lesion description</th>
<th>Local control</th>
<th>Overall survival</th>
<th>RN response</th>
<th>Resolution of symptoms</th>
<th>Steroid use</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahluwalia et al</td>
<td>2018</td>
<td>42</td>
<td>19 patients with RN (confirmed with biopsy), median lesion volume 6.4 cm³</td>
<td>PFS of 74% at 26 weeks</td>
<td>72% at 26 weeks (82.1% for RN subgroup)</td>
<td>100% (4/4) of RN treated lesions (total SLA ablation) showed complete response</td>
<td>NA</td>
<td>37% reduced or stopped steroid use at 12 weeks</td>
<td>NA</td>
</tr>
<tr>
<td>Rao et al</td>
<td>2014</td>
<td>15</td>
<td>Intracranial recurrent enhancing lesions (BM or RN). Average lesion size was 3.7 cm³</td>
<td>PFS of 75.8% at 24 weeks</td>
<td>57% at 37 weeks</td>
<td>NA</td>
<td>NA</td>
<td>5/7 symptomatic patients had resolution/decrease of symptoms</td>
<td>NA</td>
</tr>
<tr>
<td>Hong et al</td>
<td>2019</td>
<td>75</td>
<td>33 patients with RN, 18 treated with SLA, mean volume of 6.29 cm³, all lesions were 100% ablated</td>
<td>87.8% local PFS at 1 year</td>
<td>69% at 1 year</td>
<td>NA</td>
<td>87% improved in symptoms</td>
<td>34.8% weaned off steroids</td>
<td>NA</td>
</tr>
<tr>
<td>Rammo et al</td>
<td>2018</td>
<td>10</td>
<td>All patients with biopsy confirmed RN, 86% lesion volume ablated</td>
<td>NA</td>
<td>64.8% at 1 year</td>
<td>69% with RN volume decrease at 6 months</td>
<td>NA</td>
<td>7/10 weaned off steroids</td>
<td>4 patients with neurological deficit</td>
</tr>
<tr>
<td>Smith et al</td>
<td>2016</td>
<td>25</td>
<td>All patients with biopsy confirmed grade 3 and 4 RN</td>
<td>PFS time: 9.1 months</td>
<td>OS time: 39.2 months</td>
<td>5/15 with mean 26.2% decrease in size at 6 months</td>
<td>NA</td>
<td>3/7 weaned off steroids</td>
<td>NA</td>
</tr>
<tr>
<td>Chaunzwa et al</td>
<td>2018</td>
<td>30</td>
<td>Intracranial recurrent enhancing lesions (BM or RN). 19 lesions were biopsy-confirmed RN</td>
<td>NA</td>
<td>26.1% at 1 year</td>
<td>77% decrease in FLAIR volume at 6 months</td>
<td>32% with resolution of symptoms</td>
<td>63% weaned off steroids</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: BM, brain metastasis; FLAIR, fluid attenuated inversion recovery; NA, not available; OS, overall survival; PFS, progression-free survival; RN, radiation necrosis; SLA, stereotactic laser ablation; SRS, stereotactic radiosurgery.
Leptomeningeal Disease
Leptomeningeal disease involves the seeding of BM cells along the pia mater, arachnoid mater, and the cerebrospinal fluid (CSF)-filled subarachnoid space. It is a dreaded complication of cancer, with an extremely poor prognosis of survival that ranged 8 weeks to 6 months. There has been no definitive conclusion as to whether SRS increases the risk of leptomeningeal disease. However, a recent systematic review suggests patients treated with SRS are at increased risk for developing leptomeningeal disease when the primary tumor histology was breast cancer.\(^8^0\) Several studies have compared outcomes of SRS alone with resection surgery + SRS and identified an increased risk of leptomeningeal disease in the former.\(^8^1–^8^3\) The underlying premise is that surgical manipulation disperses cancer cells into the CSF space. Incidence of leptomeningeal disease after surgical resection with or without postresection SRS ranges 10 to 20%.\(^8^1,^8^3\) The type of leptomeningeal disease that occurs after surgery, however, appears to differ from that which develops without surgery. On MRI, leptomeningeal disease that occurs after surgery, however, appears to differ from that which develops without surgery. On MRI, the nodular leptomeningeal disease is associated with improved overall survival.\(^5^8,^8^4\)

There is an increasing number of studies suggesting that the risk of leptomeningeal after surgery can be mitigated by neoadjuvant SRS prior to surgical resection\(^8^5–^8^8\) (Table 3). Reported incidence of leptomeningeal disease for patients treated with neoadjuvant SRS followed by surgery ranged from 5 to 10%. Further investigation into this novel paradigm is warranted.

Radiation Necrosis and Other Complication from SRS
RN is a poorly defined term that refers to MR changes occurring at or in proximity to a BM treated by SRS or WBRT. These findings can include new regions of contrast enhancement, increased FLAIR abnormality, or a combination of both.\(^3^1,^8^9\) Histological features of RN include coagulative and liquefactive necrosis of the white matter, thickened hyalinization of vessels, as well as a variable density of reactive cells and inflammatory cells.\(^9^0\) While some tumor cells may be present, the threshold for determining active tumor versus RN is poorly defined and vary widely between pathologists.

The true incidence of RN following SRS for BM is difficult to estimate given the lack of a standardized definition.\(^8^9,^9^0\) Reported incidence ranges from 5 to 30%\(^9^1,^9^2,^6^3,^7^0\). Most RN occur within 2 years of SRS;\(^4^4\) though delayed RN decades after SRS has been reported.\(^9^1\) Most RN are not associated with neurologic deterioration, though up to 54% of patients with RN may be symptomatic.\(^9^2\) Risk factors for SRS-induced RN include radiation dose,\(^4^4,^6^3\) repeat SRS,\(^7^0\) and tumor mutations.\(^9^2\)

Patients with asymptomatic RN are monitored with surveillance imaging.\(^9^0\) Symptomatic RN are typically managed with corticosteroid treatment.\(^9^0\) For patients whose RN symptoms are refractory to corticosteroid treatment, bevacizumab therapy,\(^9^3\) hyperbaric oxygen,\(^9^4,^9^5\) surgical resection,\(^1^5,^9^6\) or SLA are considered.\(^9^7\) Of these treatments, laser ablation shows tremendous promise in terms of efficacy. In independent studies involving retrospective and prospective design, SLA has significant steroid-sparing effects on symptomatic RN.\(^7^3,^9^7–^9^9\) More than 85% of the RN treated with SLA resolve on subsequent MRI\(^7^5,^1^0^0–^1^0^2\) (Table 4).

Conclusion
BM is a frequent sequela of systemic cancer. For patients with oligometastatic BM, SRS is preferred to WBRT given the deleterious effects of the latter on neurocognition. Optimizing clinical decisions in SRS-treated BM patients requires reliable prognostication through synthesis of information pertaining to the condition of the patient, the characteristics of the tumor, and the availability of efficacious systemic therapy. Thoughtful consideration in terms of the number of metastasis and CITV is warranted when considering SRS. Local recurrence, distant recurrence, leptomeningeal disease, and RN present challenges in SRS-treated BM patients. Emerging literature suggests new technology platforms, including stereotactic laser thermal ablation,\(^7^2\) show promise in navigating these challenges.

Conflict of Interest
None declared.

References
5. Davey P. Brain metastases: treatment options to improve outcomes. CNS Drugs 2002;16(05):325–338
31 Yamamoto M, Serizawa T, Higuchi Y, et al. A multi-institutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases [JLGK0901 Study Update]: irradiation-related complications and long-term mainte-
Stereotactic Radiosurgery as Treatment for Brain Metastases

Peña-Pino, Chen

58 Ko PH, Kim HJ, Lee JS, Kim WC. Tumor volume and sphericity as predictors of local control after stereotactic radiosurgery for limited number (1–4) brain metastases from nonsmall cell lung cancer. Asia Pac J Clin Oncol 2020;16(03):165–171


